CSIMarket
 
Bioventus Inc   (BVS)
Other Ticker:  
 
 
Price: $5.4500 $0.26 5.010%
Day's High: $5.55 Week Perf: 2.64 %
Day's Low: $ 5.13 30 Day Perf: 23.58 %
Volume (M): 262 52 Wk High: $ 6.08
Volume (M$): $ 1,430 52 Wk Avg: $3.41
Open: $5.13 52 Wk Low: $0.80



 Market Capitalization (Millions $) 342
 Shares Outstanding (Millions) 63
 Employees -
 Revenues (TTM) (Millions $) 512
 Net Income (TTM) (Millions $) -196
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 7

Bioventus Inc
Bioventus Inc. is a global medical technology company that focuses on orthobiologics and orthopedic solutions. The company develops and manufactures innovative products designed to help patients with musculoskeletal conditions and injuries. These products include treatments for osteoarthritis, joint pain, cartilage damage, and bone fractures. Bioventus has a diverse portfolio of products, including surgical and non-surgical options, as well as drugs and devices. The company is committed to improving patient outcomes and quality of life through its advanced orthopedic solutions.


   Company Address: 4721 Emperor Boulevard Durham 27703 NC
   Company Phone Number: 474-6700   Stock Exchange / Ticker: NASDAQ BVS
   BVS is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bioventus Inc

Bioventus Inc. Achieves Remarkable Growth in Fiscal Fourth Quarter of 2023

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, recently announced its fourth quarter and full-year financial results for the year ended December 31, 2023. The company also provided its financial guidance for full-year 2024, indicating a positive outlook for the future.
In addition to its financial achievements, Bioventus made headlines with Amendment No. 5 to its Credit and Guaranty Agreement. This amendment, executed on January 18, 2024, demonstrates the company's commitment to optimizing its financial structure and solidifying its position as a frontrunner in regenerative medicine.

Financing Agreement

Bioventus Enhances Financial and Operational Flexibility through Amendment with Credit Agreement Lenders

Published Thu, Jan 18 2024 9:15 PM UTC



Bioventus Inc. (Bioventus), a renowned global leader in active healing innovations, recently announced a significant milestone in its financial and operational strategies. The company entered into Amendment No. 5 to its Credit and Guaranty Agreement, paving the way for enhanced flexibility and opportunities for growth. With this amendment, Bioventus aims to solidif...

Shares

Bioventus Strengthens Leadership with Inducement Equity Awards to Newly Appointed CEO

Published Fri, Jan 12 2024 9:15 PM UTC



Durham-based global leader in innovations for active healing, Bioventus Inc. (Nasdaq: BVS), recently announced the issuance of inducement equity awards to Robert (Rob) Claypoole, who has been appointed as the President and Chief Executive Officer, as well as the Principle Executive Officer of the company. This move marks an important step forward for Bioventus, as ...

Bioventus Inc

Bioventus Inc's Q3 2023 Financial Report Shows Signs of Recovery, But Challenges Persist



Bioventus Inc, a leading player in the Medical Equipment & Supplies sector, recently released its financial performance report for the third quarter of 2023. While the company's strategic moves showcased signs of recovery, the figures reveal a mixed bag of results. This article delves into the highlights of the report and offers insights into the challenges faced by Bioventus Inc in the current market.
Financial Performance Overview
In the fiscal span from July to September 2023, Bioventus Inc experienced a significant improvement in its bottom line. With a loss of $-0.12 per share, the company demonstrated improvement compared to last year's $-1.76 per share loss. Additionally, the shortfall decreased from $-0.06 per share in the previous reporting period.

Bioventus Inc

Bioventus Inc Soars to New Heights, Achieving Remarkable Financial Growth in Latest Fiscal Year Ending July 01, 2023



Bioventus Inc, a Medical Equipment & Supplies company, recently released its financial results for the fiscal second quarter of 2023. The company witnessed a mixed bag of financial performance, with losses extending per share but a significant improvement in revenue. This article aims to interpret these results and speculate on their potential impact on Bioventus Inc's future.
1. Increased Losses:
Bioventus Inc experienced an increase in losses per share, with $-0.06 compared to $-0.02 in the previous year. This indicates a potential concern for investors and stakeholders, highlighting the company's challenges in achieving profitability.






 

Bioventus Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bioventus Inc does not provide revenue guidance.

Earnings Outlook
Bioventus Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com